The Oncology Institute, Inc.
The Oncology Institute, Inc. Fundamental Analysis
The Oncology Institute, Inc. (TOIIW) shows strong financial fundamentals with a PE ratio of -41.62, profit margin of -14.38%, and ROE of 21.04%. The company generates $0.0B in annual revenue with strong year-over-year growth of 21.33%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 79.9/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze TOIIW's fundamental strength across five key dimensions:
Efficiency Score
WeakTOIIW struggles to generate sufficient returns from assets.
Valuation Score
ExcellentTOIIW trades at attractive valuation levels.
Growth Score
ExcellentTOIIW delivers strong and consistent growth momentum.
Financial Health Score
ExcellentTOIIW maintains a strong and stable balance sheet.
Profitability Score
WeakTOIIW struggles to sustain strong margins.
Key Financial Metrics
Is TOIIW Expensive or Cheap?
P/E Ratio
TOIIW trades at -41.62 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, TOIIW's PEG of -7.08 indicates potential undervaluation.
Price to Book
The market values The Oncology Institute, Inc. at -224.75 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -6.22 times EBITDA. This is generally considered low.
How Well Does TOIIW Make Money?
Net Profit Margin
For every $100 in sales, The Oncology Institute, Inc. keeps $-14.38 as profit after all expenses.
Operating Margin
Core operations generate -8.92 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $21.04 in profit for every $100 of shareholder equity.
ROA
The Oncology Institute, Inc. generates $-40.51 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
The Oncology Institute, Inc. generates limited operating cash flow of $-2.39M, signaling weaker underlying cash strength.
Free Cash Flow
The Oncology Institute, Inc. generates weak or negative free cash flow of $-2.78M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.03 in free cash annually.
FCF Yield
TOIIW converts -9.77% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-41.62
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-7.08
vs 25 benchmark
P/B Ratio
Price to book value ratio
-224.75
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.60
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-2.23
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.68
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
21.04
vs 25 benchmark
ROA
Return on assets percentage
-0.41
vs 25 benchmark
ROCE
Return on capital employed
-0.42
vs 25 benchmark
How TOIIW Stacks Against Its Sector Peers
| Metric | TOIIW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -41.62 | 29.45 | Better (Cheaper) |
| ROE | 2103.96% | 779.00% | Excellent |
| Net Margin | -14.38% | -24936.00% (disorted) | Weak |
| Debt/Equity | -2.23 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 1.68 | 4.65 | Neutral |
| ROA | -40.51% | -19344.00% (disorted) | Weak |
TOIIW outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROE, but lagging in Net Margin.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews The Oncology Institute, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
117.40%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-1280.90%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-730.40%
Industry Style: Defensive, Growth, Innovation
Declining